Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Herantis Pharma Oyj
OYJ
Active
Y-tunnus 2198665-7
Bertel Jungin Aukio 1, 02600
Espoo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2008 · 18 years old
— employees
www.herantis.com
Share
Finland
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Herantis Pharma Oyj
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
EUR millions
0M
1M
3M
4M
6M
0M
2021
0M
2022
5M
2023
0M
2024
0M
2025
EBITDA
EUR millions
0M
-3M
-6M
-8M
-11M
-9M
2021
-8M
+11%
2022
0M
+100%
2023
-5M
-500%
2024
-6M
-20%
2025
Income statement
EUR thousands
Item
2021
2022
2023
2024
2025
Revenue
0
0
5 307
0
0
Staff expenses
−2 246
−2 649
−173 516
−1 488
−1 921
EBITDA
−8 890
−7 833
154
−5 026
−6 396
Depreciation & amort.
−160
−160
−0
−0
−0
EBIT
−9 050
−7 993
15 437
−5 026
−6 396
Net financials
−14 526
−1 331
125
87
−224
Profit before tax
−23 576
−9 324
280
−4 883
−6 620
Tax
−0
−0
−0
−0
−0
Net profit
−23 576
−9 324
280
−4 939
−6 620
Balance sheet
EUR thousands
Item
2021
2022
2023
2024
2025
Total assets
6 918
6 232
674 564
2 571
2 668
Equity
554
−60
472 635
−243
−1 688
Long-term debt
4 469
4 391
2 985
2 180
3 443
Short-term debt
1 895
1 902
198 944
634
913
Total debt
6 364
6 292
201 929
2 814
4 356
Financial ratios
5-year trend
EBITDA margin
-639567200.0%
This company
15.8%
Market median
-4047893771% vs market
2021
2025
Equity ratio
-63.2%
This company
38.2%
Market median
-265% vs market
2021
2025
Return on equity
-662014500.0%
This company
18.4%
Market median
-3597904991% vs market
2021
2025
Net profit margin
-662014500.0%
This company
8.1%
Market median
-8173018619% vs market
2021
2025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2021
2025
Debt / equity
2.58×
This company
0.62×
Market median
-316% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
View
PDF
More on Herantis Pharma Oyj
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
